Drug Trial Radar · NCT06387069
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
316
Planned (sponsor's estimate)
Start
Apr 26, 2024
Primary completion
Dec 31, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Apr 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, open-label, phase III clinical study (RAPHAEL) to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with R/R AML harboring IDH1 and IDH2 mutations.
Conditions
- Acute Myeloid Leukemia
Interventions
HMPL-306 RegimenDrug
Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
Salvage Chemotherapy RegimenDrug
Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition: * EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5). * FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 1000-2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4). * LoDAC: -Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10). * Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7).
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: Up to approximately 33 months
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China · Recruiting
Tianjin People's Hospital
Tianjin, China · Recruiting
Anhui Provincial Hospital(The First Affiliated Hospital of U STC)
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
The First Affilated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Quanzhou First Hospital Affiliated to Fujian Medical University
Quanzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangzhou First People's Hospital
Guangzhou, Guangdong, China · Recruiting
Nanfang Hospital,Southern Medical University
Guanzhou, Guangdong, China · Recruiting
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China · Recruiting
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
Affiliated Hospital of Zunyi Medical Univercity
Zunyi, Guizhou, China · Recruiting
Baoding NO.1 Central Hospital
Baoding, Hebei, China · Recruiting
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China · Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin First Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affilated Hospital of Henan University of Science & Technology
Luoyang, Henan, China · Recruiting
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Wuhan Union Hospital of China
Wuhan, Hubei, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
People's Hospital of Hunan Province
Changsha, Hunan, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Wuxi People's Hospital
Wuxi, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.